Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02343133 · ClinicalTrials.gov registry record · Phase 2
Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome
A Phase 2 study of Hematopoietic Syndrome Due to Acute Radiation Syndrome, sponsored by Neumedicines.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 4
- Study locations
NCT02343133 is a Phase 2 study of Hematopoietic Syndrome Due to Acute Radiation Syndrome that has completed, run by Neumedicines. The registered enrollment target is 200 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT02343133, a Phase 2 study of Hematopoietic Syndrome Due to Acute Radiation Syndrome, has completed, sponsored by Neumedicines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine whether HemaMax is safe and well tolerated to support efficacy under FDA's Animal Rule to reduce the morbidity and mortality associated with the hematopoietic syndrome of acute radiation syndrome.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL HemaMax
Study Locations (4)
Florida
- Covance Clinical Research Unit - Daytona Beach
Indiana
- Covance Clinical Research Unit - Evansville
Texas
- Covance Clinical Research Unit - Dallas
Wisconsin
- Covance Clinical Research Unit - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02343133
The ClinicalTrials.gov registry entry for NCT02343133 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neumedicines, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematopoietic Syndrome Due to Acute Radiation Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02343133 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Indiana, Texas.
Frequently Asked Questions
What is clinical trial NCT02343133 about?
NCT02343133 is a clinical study titled "Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome". The purpose of this study is to determine whether HemaMax is safe and well tolerated to support efficacy under FDA's Animal Rule to reduce the morbidity and mortality associated with the hematopoietic syndrome of acute radiation syndrome.
What is the current status of trial NCT02343133?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2015-01. Estimated completion is 2016-04.
What conditions does trial NCT02343133 study?
This clinical trial studies the following conditions: Hematopoietic Syndrome Due to Acute Radiation Syndrome.
What interventions are being tested in trial NCT02343133?
The interventions under investigation include: Placebo (DRUG), HemaMax (BIOLOGICAL).
Who is sponsoring clinical trial NCT02343133?
This trial is sponsored by Neumedicines, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02343133 being conducted?
This trial has 4 study locations across Florida, Indiana, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.